Literature DB >> 16626923

Malignancies following bilateral salpingo-oophorectomy (BSO).

W H Gotlieb1, M Barchana, G Ben-Baruch, E Friedman.   

Abstract

AIMS: Prophylactic bilateral salpingo-oophorectomy (BSO) is an effective risk reducing measure in ovarian cancer susceptible women. Yet, a small subset of women develop primary peritoneal carcinomatosis (PPC) after BSO. The rates of PPC following non-risk reducing BSO have sparingly been reported.
METHODS: Women who underwent BSO for non-cancer reasons from 1/1/1984 to 12/31/2000 were crossed with the list of cancer diagnoses reported to the Israel National Cancer Registry until 12/31/2001.
RESULTS: Overall, 4128 women at a mean age of 58+/-12 years were analyzed. After a mean of 7.2+/-4 years following BSO, 147 women (3.6%) were diagnosed with cancer: breast cancer in 50 women 62+/-50 months after BSO, and one patient developed PPC, whereas the expected was 0.15 cases. The Standardized Incidence Ratio (SIR) of developing breast cancer was statistically significant lower than expected (SIR 0.71, 95% C.I. 0.44-0.78).
CONCLUSION: The rate of post-oophorectomy PPC in average risk population is low, and BSO appears to lower the rate of breast cancer in average risk women.

Entities:  

Mesh:

Year:  2006        PMID: 16626923     DOI: 10.1016/j.ejso.2006.03.021

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  2 in total

1.  No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.

Authors:  Larissa A Korde; Christine M Mueller; Jennifer T Loud; Jeffery P Struewing; Kathy Nichols; Mark H Greene; Phuong L Mai
Journal:  Breast Cancer Res Treat       Date:  2010-05-11       Impact factor: 4.872

2.  Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.

Authors:  Ying Chen; Elizabeth Bancroft; Sue Ashley; Audrey Arden-Jones; Sarah Thomas; Susan Shanley; Sibel Saya; Emma Wakeling; Rosalind Eeles
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.